Northwest Biotherapeutics

Northwest Biotherapeutics (also known as NW Bio) is a biotechnology company that specializes in the development of immunotherapy products to treat cancer. The company was founded in 1996 and is headquartered in Bethesda, Maryland, United States.

History

Northwest Biotherapeutics was established in 1996 with the aim of developing novel therapeutic approaches to treat cancer. The company's primary focus is on the development of personalized immunotherapy treatments that utilize a patient's own immune system to fight cancer.

Products and Research

Northwest Biotherapeutics' lead product, DCVax-L, is a personalized vaccine designed to stimulate an immune response against cancer cells. DCVax-L is currently in clinical trials for the treatment of glioblastoma, a type of brain cancer.

In addition to DCVax-L, the company is also developing DCVax-Direct, a product designed for the treatment of inoperable solid tumors. This product is also currently in clinical trials.

Clinical Trials

The company's products are in various stages of clinical trials. The most advanced of these is DCVax-L, which is in Phase III clinical trials for the treatment of newly diagnosed glioblastoma. The company has also initiated a Phase I/II trial for DCVax-Direct for the treatment of inoperable solid tumors.

Financials

As a publicly traded company, Northwest Biotherapeutics' financial performance is a matter of public record. The company is listed on the NASDAQ stock exchange under the ticker symbol "NWBO".

See Also

• Biotechnology
• Immunotherapy
• Cancer
• Clinical trial
• Glioblastoma

• Logo of Northwest Biotherapeutics
  Logo of Northwest Biotherapeutics